CALTX.ST Gross Margin

The Gross Margin of Calliditas Therapeutics AB (CALTX.ST) is 94.99%.

Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.

CALTX.ST Gross Margin - Historical Value

Date	Value
2023-12-31	94.99%
2022-12-31	98.11%

CALTX.ST Gross Margin - Peers Comparison

Ticker	Name	Value
LIPI.ST	Lipidor AB	-82.31%
HYL.BR	Hyloris Pharmaceuticals SA	70.86%
KDEV.ST	Karolinska Development AB	-350.07%
RLS.ST	RLS Global AB	-34.31%
VISTN.OL	Vistin Pharma ASA	65.08%
CAMX.ST	Camurus AB	93.07%
IBT B.ST	Infant Bacterial Therapeutics AB	7775.20%
OVB.L	Ovoca Bio PLC	7775.20%
MARI.VI	Marinomed Biotech AG	12.45%
PHO.OL	Photocure ASA	94.15%
SECARE.ST	Swedencare AB (publ)	36.83%
ACPH.BR	Acacia Pharma Group PLC	74.63%
AGY.L	Allergy Therapeutics PLC	53.87%
ORX.ST	Orexo AB	87.78%
SHE.MI	Shedir Pharma Srl Unipersonale	60.29%
INDEX.ST	InDex Pharmaceuticals Holding AB	-81.95%
MOB.ST	Moberg Pharma AB (publ)	64.37%
EAH.L	ECO Animal Health Group PLC	42.14%
ENZY.ST	Enzymatica AB (publ)	67.40%
IRLAB A.ST	IRLAB Therapeutics AB	-44.03%
MITRA.BR	Mithra Pharmaceuticals SA	45.34%
ADVIC.PA	Advicenne SA	-49723.60%
AMYT.L	Amryt Pharma PLC	3481.68%
ERMA.ST	Enorama Pharma AB	23.48%
OAT.WA	Oncoarendi Therapeutics SA	-26049.80%
PRL.MI	Pierrel SpA	70.15%
CLBIO.ST	Corline Biomedical AB	137.50%
CLN.WA	Celon Pharma SA	69.15%